ILA
Island Pharmaceuticals Limited
🇦🇺 ASX
📦 LOGISTICS
👑 Overview
📈 Performance
💵 Cost
🤓 Advanced
👨👩👧👦 Community
📈
-9.55%
Annual Growth
4 years average annual growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
3
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Island Pharmaceuticals Ltd. is a drug research and repurposing company, focused on developing preventative or therapeutic drugs for viral infections. The company is headquartered in Melbourne, Victoria. The company went IPO on 2021-04-13. The firm's lead asset is ISLA-101, a drug, being repurposed for the prevention and treatment of dengue fever and other mosquito (or vector) borne diseases. ISLA-101 has been shown to have activity against all four strains of dengue virus as well as other flaviviruses such as Zika virus, West Nile virus, and Yellow Fever virus, as well as Chikungunya virus. The firm operates a single segment, being research and development activities principally in the geographic regions of Australia and the United States. Its subsidiary is Isla Pharmaceuticals Inc.
📈 Performance
Price History
-36.00%
1M
1Y
All Time
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
💰 Price*
$0.16
*Price may be up to 24 hours old
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in ILA
3
📊 Total Capital Earnings
N/A
🔃 Average investment frequency
19 weeks
💵 Average investment amount
$1,182
⏰ Last time a customer invested in ILA
10 days
ILA investor breakdown
💵 Income of investors
More than 200k
150k - 200k
20%
100k - 150k
40%
50k - 100k
Less than 50k
40%
👶 Age of investors
18 - 25
26 - 34
67%
35 - 90
33%
🙋 Legal gender of investors
Female
Male
100%
Pearlers who invest in ILA also invest in...
VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.
🙌 Performance (5Yr p.a)
2.87%
📊 Share price
$102.49 AUD
🇦🇺 AUSTRALIA
🧱 MATERIALS
💸 FINANCIALS
⛳️ DIVERSIFIED
VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.
🙌 Performance (5Yr p.a)
13.35%
📊 Share price
$141.02 AUD
🌏 GLOBAL
🤖 TECHNOLOGY
⛳️ DIVERSIFIED
📈 HIGH PRICE GROWTH
PharmAust Ltd. engages in the business of developing own drug discovery intellectual property for the treatment of different types of cancers, neurological diseases, and viral infections; and providing highly specialized medicinal and synthetic chemistry services on a contract basis to clients. The company is headquartered in South Melbourne, Victoria. The company went IPO on 2001-10-05. The Company’s segments include Corporate and Research. The firm is focused on repurposing monepantel (MPL) for human neurodegenerative diseases. The firm's lead candidate, Monepantel (MPL), is a potent and safe inhibitor of the mTOR pathway, that plays a central role in cell growth and proliferation of cancer cells and in degenerating neurons. The firm is also developing MPL as a treatment for motor neuron disease (MND/ALS), a rare, incurable disease. The company is focused on starting Phase II/III clinical study of MPL. The company has also completed a Phase II oncology clinical study of MPL in humans and pilot studies in canine cancer. The company is also preparing a pivotal monepantel field trial in dogs with B-Cell Lymphoma to enable product registration in the United States.
🙌 Performance (5Yr p.a)
15.38%
📊 Share price
$0.23 AUD
📦 LOGISTICS
📈 HIGH PRICE GROWTH
A200.AX was created on 2018-05-07 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. A200.AX aims to track the performance of an index (before fees and expenses) comprising 200 of the largest companies by market capitalisation listed on the ASX.
🙌 Performance (5Yr p.a)
3.41%
📊 Share price
$138.15 AUD
⛳️ DIVERSIFIED
💸 FINANCIALS
🇦🇺 AUSTRALIA
Neurizon Therapeutics Ltd is a AU-based company operating in Pharmaceuticals industry. The company is headquartered in South Melbourne, Victoria. The company went IPO on 2001-10-05. Neurizon Therapeutics Ltd, formerly PharmAust Limited, is an Australia-based clinical-stage biotechnology company. The firm is engaged in advancing treatments for neurodegenerative diseases. The firm is focused on developing its lead drug candidate, NUZ-001, for the treatment of Amyotrophic Lateral Sclerosis (ALS), which is the common form of motor neuron disease. ALS is a devastating neurodegenerative condition that primarily affects nerve cells that control voluntary muscles.
🙌 Performance (5Yr p.a)
11.46%
📊 Share price
$0.14 AUD
📈 HIGH PRICE GROWTH
📦 LOGISTICS
Want more shares? Try these...
ILB.AX was created on 2012-03-12 by iShares. The fund's investment portfolio concentrates primarily on investment grade fixed income. The fund aims to provide investors with the performance of the Bloomberg AusBond Inflation Government 0+ Yr Index, before fees and expenses. The index is designed to measure the performance of a segment of the Australian bond market comprised of inflation-linked fixed income securities.
🙌 Performance (5Yr p.a)
-0.82%
📊 Share price
$123.51 AUD
ikeGPS Group Ltd. engages in the design, sale, and delivery of a solution for the collection, analysis, and management of distribution assets for electric utilities and communications companies. The firm is engaged in design, sale, and delivery of a solution for the collection, analysis, and management of distribution assets for electric utilities and communications companies. The firm provides end-to-end technical solution for customers, it captures and analyses pole loading and make-ready engineering assessments, or customers capture pole data and transact on the platform. The company offers IKE Platform solution where customers use the functionality of IKE Office. The company offers Hardware and other services, such as IKE Device and Spike device sales, and other services including training and deployment. Its solutions include IKE Office Pro, IKE Structural, IKE Insight, IKE Analyze, and IKE University. Its IKE Office Pro is a cloud-based software platform to measure and manage poles quickly, then export them to your native systems.
🙌 Performance (5Yr p.a)
-4.83%
📊 Share price
$0.55 AUD
🔨 COMMERCIAL SERVICES & SUPPLIES
IKO.AX was created on 2000-05-09 by iShares. The fund's investment portfolio concentrates primarily on total market equity. The fund aims to provide investors with the performance of the MSCI Korea 25/50 Index, before fees and expenses. The index is designed to measure the performance of Korean large-, mid- & small- capitalisation companies
🙌 Performance (5Yr p.a)
-0.84%
📊 Share price
$91.57 AUD
⛳️ DIVERSIFIED
🤖 TECHNOLOGY
KOREA